The chart above plots the price of BIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 64 sessions over that window: $256.00 on 1 May 2026 through $327.00 on 29 July 2026. Finazon · prior-day close.
Market cap$8.9B
52-week range$242.00 – $340.00
Avg volume78.1K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026
Filings 4 sets
BIO reported financials
SEC EDGAR XBRL
BIO reported revenue of $2.6B for the fiscal year ended 31 Dec 2025. Net income over the same period was $759.9M.
FigureReportedPeriod
Revenue
$2.6B
31 Dec 2025 fiscal year
Net income
$759.9M
31 Dec 2025 fiscal year
Diluted EPS
$27.85
31 Dec 2025 fiscal year
Total assets
$9.8B
31 Mar 2026 at period end
Total equity
$6.9B
31 Mar 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026
BIO earnings
SEC EDGAR
DatePeriodEPSRevenue
31 Mar 2026Q1 2026$-19.55$592M
31 Dec 2025FY 2025$27.85$2.58B
30 Sep 2025Q3 2025$-12.70$653M
30 Jun 2025Q2 2025$11.67$652M
Reported figures & scheduled dates · SEC EDGAR filings
BIO institutional holders
SEC Form 13F
11 of the 45 institutional funds we track reported a BIO position for the quarter ended 31 Mar 2026 — a combined $144.2M; the latest of those filings landed 15 May 2026.